Prurigo Nodularis: An Older African American Female Adult Presenting With Nodular Lesions and Persistent Itching

SPONSORSHIP & SUPPORT
This educational activity is jointly provided by Global Education Group and Spire Learning.

This activity is supported by educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals.

PROGRAM OVERVIEW

Prurigo nodularis (PN) is a chronic condition mediated by immune and neural dysregulation and presenting with highly pruritic, hyperkeratotic papules or nodules; the condition disproportionately affects African American patients compared to the general population. There are currently no FDA-approved therapies for the treatment of PN, leading to a high level of variability in clinical practice and the use of off-label agents; the current treatment landscape, or lack thereof, highlights the need for a multimodal approach to therapy and consideration of emerging agents. As a result, many health care professionals may be unaware of the standard, off-label treatments used, as well as the clinical data surrounding promising emerging agents for PN management and as a result, may miss opportunities to deliver evidence-based care. Join our expert faculty as they discuss patient scenarios utilizing methods to avoid missed opportunities for the care team, assess the clinical efficacy and safety of standard off-label, as well as emerging therapies, and ultimately devise effective treatment plans that encourage long-term adherence and address residual disease burden for patients with PN.*

*At the time of this activity launch, there were no therapies FDA-approved for the treatment of PN. As of September 2022, dupilumab became the first and only FDA-approved medication to specifically treat PN.

TARGET AUDIENCE

The target audience will be comprised of dermatologists, specialty nurse practitioners, specialty physician assistants, and managed care pharmacists.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners should be better able to:

• ANALYZE clinical data surrounding emerging treatments for PN
• ASSESS the efficacy of standard, off-label treatments currently used for PN and residual burden of disease on patients
• DEVELOP evaluation criteria for prurigo nodularis (PN) that incorporates characteristic features, including symptoms, presentation, and comorbidities
• DEVISE a treatment plan that encourages long-term adherence

ACCREDITATION AND CREDIT DESIGNATION
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Spire Learning, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.25 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation Statement
Global Education Group designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-163-H01-P) This is a knowledge-based activity.

HOW TO RECEIVE CREDIT
There is no fee for this educational activity. To receive credit for your participation in this educational activity:

• Read the objectives and other introductory CME information
• Complete the preassessment prior to the start of the activity
• Participate in the prurigo nodularis case activity
• Complete the postassessment with a passing score of 70% and complete the evaluation at the conclusion of the activity

If you are seeking credit, you must complete the evaluation at the conclusion of the activity.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com 

CONFLICTS OF INTEREST STATEMENT
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

PLANNING COMMITTEE
Chesahna Kindred, MD, MBA, FAAD (Chair)
Assistant Professor of Dermatology
Howard University College of Medicine
Washington, DC
Kindred Hair & Skin Center
Columbia, MD

Disclosures:
Consulting Fees (eg, Advisory Board): Aerolase; Eli Lilly and Company; Sun Pharmaceuticals; UCB, Inc
Speakers’ Bureau: Aerolase; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Nutrafol; Sun Pharmaceuticals; UCB, Inc

Shawn Kwatra, MD, FAAD
Associate Professor of Dermatology and Oncology
Director, Johns Hopkins Itch Center
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosures:
Consulting Fees (eg, Advisory Board): AbbVie Inc; Celldex Therapeutics; Galderma; Incyte Corp; Kiniksa Pharmaceuticals; Novartis Pharmaceuticals Corp; Pfizer Inc; Regeneron Pharmaceuticals; Sanofi
Contracted Research: Galderma; Kiniksa Pharmaceuticals; Pfizer Inc; Sanofi

EDUCATIONAL PLANNING COMMITTEE
Global Education Group
Rhys Williams, MSN, FNP-C, RN; Lindsay Borvansky; Andrea Funk; Liddy Knight; Ashley Cann: No relevant financial relationships with any commercial interests.

Spire Learning
Andrew Kim, Kimberly Miniter, and Mary Simmons have nothing to disclose.

Reviewer
Lindsay Borvansky: No relevant financial relationships with any commercial interests.

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Spire Learning do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIVACY POLICY:
Spire Learning Privacy Policy:
Spire Learning, LLC, is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
 
Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC, to continuously improve the learning experience.
 
Spire Learning, LLC, will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws. 

COPYRIGHT INFORMATION:
Copyright © 2022 by Spire Learning, LLC and Global Education Group. All rights reserved including translation into other languages. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC.

COURSE VIEWING REQUIREMENTS